GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
99 hedge funds and large institutions have $657M invested in GenMark Diagnostics, Inc in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 50 increasing their positions, 13 reducing their positions, and 6 closing their positions.
285% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 13
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
15% more funds holding
Funds holding: 86 → 99 (+13)
6% more capital invested
Capital invested by funds: $618M → $657M (+$39.6M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.2M |
| 3 |
CCM
Cadian Capital Management
New York
|
+$10.2M |
| 4 |
JP Morgan Chase
New York
|
+$7.15M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$6.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.31M |
| 2 |
CRC
Curi RMB Capital
Chicago,
Illinois
|
-$6.41M |
| 3 |
Morgan Stanley
New York
|
-$4.02M |
| 4 |
Two Sigma Investments
New York
|
-$1.1M |
| 5 |
Two Sigma Advisers
New York
|
-$536K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
101
A.R.T. Advisors
New York
| – | -$406K | -31,700 | Closed |
|
|
AL
102
Airain Ltd
St. Peter Port,
Guernsey
| – | -$159K | -12,394 | Closed |
|
|
SIP
103
Stoneridge Investment Partners
Radnor,
Pennsylvania
| – | -$154K | -11,989 | Closed |
|
104
Barclays
London,
United Kingdom
| – | -$24.8K | -1,943 | -98% |
|
|
TRCT
105
Tower Research Capital (TRC)
New York
| – | -$1K | -100 | Closed |
|
GNMK Hedge Fund Activity: Q2 2017 in Review
99 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q2 2017, worth a combined $657M — up 6.4% from $618M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new GNMK positions and 6 closed out — a net gain of 13 holders — while 50 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $12.3M. The largest seller was Adage Capital Partners, cutting an estimated $8.31M.
- 99 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q2 2017, up from 86 in Q1 2017.
- Funds reported $657M of GenMark Diagnostics, Inc stock for Q2 2017, up 6.4% quarter-over-quarter.
- 19 funds opened new GenMark Diagnostics, Inc positions in Q2 2017 and 6 closed out, a net change of +13 holders.
- The largest GenMark Diagnostics, Inc buyer in Q2 2017 was Fidelity Investments, an estimated $12.3M added.
- The largest GenMark Diagnostics, Inc seller in Q2 2017 was Adage Capital Partners, an estimated $8.31M sold.
Based on aggregated 13F filings for Q2 2017.